Sarepta Acquires RNA Drugs for $500 Million
- Posted by ISPE Boston
- On December 5, 2024
Sarepta Therapeutics has inked an exclusive licensing and collaboration agreement with Arrowhead Pharmaceuticals under which Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and lungs. The agreement will add meaningfully to Sarepta’s mid- and early-stage pipeline, complementing the Company’s existing leadership in […]
Read More